63. Idiopathic thrombocytopenic purpura
311 clinical trials,   185 drugs   (DrugBank: 39 drugs),   43 drug target genes,   132 drug target pathways

Searched query = "Idiopathic thrombocytopenic purpura", "Primary immune thrombocytopenia"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
1 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2014-001429-33-PL
(EUCTR)
07/12/201509/10/2015Study to evaluate safety and efficacy in adult subjects with ITPOpen Label, Adaptive Design, Ascending, Multiple-Dose Study to Evaluate Safety and Efficacyof BMS-986004 in Adult Subjects with Primary Immune Thrombocytopenia (ITP) Immune Thrombocytopenia
MedDRA version: 19.1;Level: LLT;Classification code 10036735;Term: Primary thrombocytopenia;System Organ Class: 100000004851;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Product Name: Anti-CD40LdAb
Product Code: BMS-986004
INN or Proposed INN: N/A
Other descriptive name: anti-CD40L
Bristol-Myers Squibb International CorporationNULLNot RecruitingFemale: yes
Male: yes
80Phase 2United States;Canada;Poland;Australia;Russian Federation;Georgia;Moldova, Republic of